EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2
EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	osimertinib + afatinib Sensitive: B - Late Trials osimertinib + afatinib Sensitive : B	osimertinib + afatinib Sensitive: B - Late Trials osimertinib + afatinib Sensitive : B
EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3
EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3
EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	gefitinib Resistant: C3 – Early Trials gefitinib Resistant : C3	gefitinib Resistant: C3 – Early Trials gefitinib Resistant : C3
EGFR L858R + EGFR T790M	Lung Non-Small Cell Squamous Cancer	EGFR L858R + EGFR T790M	Lung Non-Small Cell Squamous Cancer	gefitinib Resistant: C4 – Case Studies gefitinib Resistant : C4	gefitinib Resistant: C4 – Case Studies gefitinib Resistant : C4
EGFR L858R + EGFR T790M	Lung Adenocarcinoma	EGFR L858R + EGFR T790M	Lung Adenocarcinoma	aumolertinib Sensitive: C4 – Case Studies aumolertinib Sensitive : C4	aumolertinib Sensitive: C4 – Case Studies aumolertinib Sensitive : C4
EGFR L858R + EGFR T790M	Lung Cancer	EGFR L858R + EGFR T790M	Lung Cancer	osimertinib Sensitive: C4 – Case Studies osimertinib Sensitive : C4	osimertinib Sensitive: C4 – Case Studies osimertinib Sensitive : C4
EGFR L858R + EGFR T790M	Lung Adenocarcinoma	EGFR L858R + EGFR T790M	Lung Adenocarcinoma	gefitinib Resistant: D – Preclinical gefitinib Resistant : D	gefitinib Resistant: D – Preclinical gefitinib Resistant : D
EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	CH7233163 Sensitive: D – Preclinical CH7233163 Sensitive : D	CH7233163 Sensitive: D – Preclinical CH7233163 Sensitive : D
EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	rociletinib Sensitive: D – Preclinical rociletinib Sensitive : D	rociletinib Sensitive: D – Preclinical rociletinib Sensitive : D
EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	osimertinib + BX795 Sensitive: D – Preclinical osimertinib + BX795 Sensitive : D	osimertinib + BX795 Sensitive: D – Preclinical osimertinib + BX795 Sensitive : D
EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	H002 Sensitive: D – Preclinical H002 Sensitive : D	H002 Sensitive: D – Preclinical H002 Sensitive : D
EGFR L858R + EGFR T790M	Lung Cancer	EGFR L858R + EGFR T790M	Lung Cancer	osimertinib + tipifarnib Sensitive: D – Preclinical osimertinib + tipifarnib Sensitive : D	osimertinib + tipifarnib Sensitive: D – Preclinical osimertinib + tipifarnib Sensitive : D
EGFR L858R + EGFR T790M	Melanoma	EGFR L858R + EGFR T790M	Melanoma	doxorubicin hydrochloride Resistant: D – Preclinical doxorubicin hydrochloride Resistant : D	doxorubicin hydrochloride Resistant: D – Preclinical doxorubicin hydrochloride Resistant : D
EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	KKI04 Sensitive: D – Preclinical KKI04 Sensitive : D	KKI04 Sensitive: D – Preclinical KKI04 Sensitive : D

EGFR L858R + EGFR T790M

Associations